These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 23041585)

  • 61. A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study.
    Mannel RS; Brady MF; Kohn EC; Hanjani P; Hiura M; Lee R; Degeest K; Cohn DE; Monk BJ; Michael H
    Gynecol Oncol; 2011 Jul; 122(1):89-94. PubMed ID: 21529904
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A comparison of primary intraperitoneal chemotherapy to consolidation intraperitoneal chemotherapy in optimally resected advanced ovarian cancer.
    Suidan RS; St Clair CM; Lee SJ; Barlin JN; Long Roche KC; Tanner EJ; Sonoda Y; Barakat RR; Zivanovic O; Chi DS
    Gynecol Oncol; 2014 Sep; 134(3):468-72. PubMed ID: 25042672
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma.
    Safra T; Menczer J; Bernstein RM; Shpigel S; Matcejevsky D; Inbar MJ; Golan A; Grisaru D; Levy T
    Gynecol Oncol; 2009 Aug; 114(2):215-8. PubMed ID: 19446318
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Weekly carboplatin with paclitaxel compared to standard three-weekly treatment in advanced epithelial ovarian carcinoma--a retrospective study.
    Safra T; Shamai S; Greenberg J; Veizman A; Shpigel S; Matcejevsky D; Pelles S; Inbar M; Levy T; Grisaru D
    Gynecol Oncol; 2014 Jan; 132(1):18-22. PubMed ID: 23850468
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study.
    De Placido S; Scambia G; Di Vagno G; Naglieri E; Lombardi AV; Biamonte R; Marinaccio M; Cartenì G; Manzione L; Febbraro A; De Matteis A; Gasparini G; Valerio MR; Danese S; Perrone F; Lauria R; De Laurentiis M; Greggi S; Gallo C; Pignata S
    J Clin Oncol; 2004 Jul; 22(13):2635-42. PubMed ID: 15226331
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The Prognostic Impact of the Pathological Response to Neoadjuvant Dose-Dense Therapy for Ovarian Carcinoma.
    Ebata T; Yunokawa M; Yoshida H; Bun S; Shimoi T; Shimomura A; Kodaira M; Yonemori K; Shimizu C; Fujiwara Y; Kato T; Tamura K
    Int J Gynecol Cancer; 2017 Nov; 27(9):1850-1855. PubMed ID: 29040183
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy.
    Miao Y; Yan Q; Li S; Li B; Feng Y
    Cancer Biomark; 2016 Jun; 17(1):33-40. PubMed ID: 27314290
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A retrospective evaluation of the feasibility of intrapatient dose escalation as appropriate methodology for dose-ranging studies for combination cytotoxic regimens.
    Jordan SD; Poole CJ; Archer VR; Steven NM; Burton A
    Cancer Chemother Pharmacol; 2003 Aug; 52(2):113-8. PubMed ID: 12783201
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Prognostic factors for early-stage epithelial ovarian cancer, treated with adjuvant carboplatin/paclitaxel chemotherapy: a single institution experience.
    Bamias A; Karadimou A; Soupos N; Sotiropoulou M; Zagouri F; Haidopoulos D; Thomakos N; Rodolakis A; Antsaklis A; Dimopoulos MA
    Gynecol Oncol; 2011 Oct; 123(1):37-42. PubMed ID: 21764430
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Retrospective analysis of the survival benefit of chemotherapy for recurrent or advanced epithelial ovarian carcinoma in patients previously treated with paclitaxel plus platinum-based chemotherapy.
    Nishikawa A; Hashimoto H; Takeda M; Kontani K; Miyatake T; Mimura M; Nagamatsu M; Yokoi T
    Eur J Gynaecol Oncol; 2016 Aug; 37(4):451-454. PubMed ID: 29894065
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma.
    Becker DA; Thomas ED; Gilbert AL; Boone JD; Straughn JM; Huh WK; Bevis KS; Leath CA; Alvarez RD
    Gynecol Oncol; 2016 Jul; 142(1):25-29. PubMed ID: 27130405
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The use of weekly topotecan in the treatment of heavily pretreated recurrent epithelial ovarian and primary peritoneal cancer: the Kaohsiung Chang Gung experience.
    Hu CF; Ou YC; Fu HC; Chang Chien CC; Tsai CC; Wu CH; Lin H
    Taiwan J Obstet Gynecol; 2015 Feb; 54(1):43-7. PubMed ID: 25675918
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer--a population-based study.
    Jordan S; Steer C; DeFazio A; Quinn M; Obermair A; Friedlander M; Francis J; O'Brien S; Goss G; Wyld D; Australian Ovarian Cancer Study Group ; Webb P;
    Gynecol Oncol; 2013 May; 129(2):310-7. PubMed ID: 23403164
    [TBL] [Abstract][Full Text] [Related]  

  • 74. One year maintenance of carboplatin in patients with epithelial ovarian cancer--a phase II study.
    Safra T; Kovner F; Barak N; Inbar MJ; Ron IG
    Isr Med Assoc J; 2006 Jan; 8(1):27-9. PubMed ID: 16450747
    [TBL] [Abstract][Full Text] [Related]  

  • 75. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
    Aghajanian C; Blank SV; Goff BA; Judson PL; Teneriello MG; Husain A; Sovak MA; Yi J; Nycum LR
    J Clin Oncol; 2012 Jun; 30(17):2039-45. PubMed ID: 22529265
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Prediction of toxicity but not of clinical course by determining carboplatin exposure in patients with epithelial ovarian cancer treated with a combination of carboplatin and cisplatin.
    Obermair A; Speiser P; Thoma M; Kaider A; Salzer H; Dittrich C; Sevelda P
    Int J Oncol; 1998 Nov; 13(5):1023-30. PubMed ID: 9772295
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC).
    Seifert H; Georgiou A; Alexander H; McLachlan J; Bodla S; Kaye S; Barton D; Nobbenhuis M; Gore M; Banerjee S
    Gynecol Oncol; 2015 Nov; 139(2):216-20. PubMed ID: 26318078
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome.
    Fagotti A; Ferrandina G; Vizzielli G; Fanfani F; Gallotta V; Chiantera V; Costantini B; Margariti PA; Gueli Alletti S; Cosentino F; Tortorella L; Scambia G
    Eur J Cancer; 2016 May; 59():22-33. PubMed ID: 26998845
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.